2019
Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging
Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer Research 2019, 25: 1226-1232. PMID: 30487127, PMCID: PMC7462306, DOI: 10.1158/1078-0432.ccr-18-2079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCell SizeChemoradiotherapyDisease ProgressionDose Fractionation, RadiationFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm, ResidualSodiumTumor BurdenConceptsResidual tumor volumeTumor cell killTissue sodium concentrationChemoradiation therapyOverall survivalHuman glioblastomaTumor volumeQuantitative sodium MR imagingCell killQuantitative sodium MRITumor cellsVariable tumor responseSodium MRITwo-compartment modelTumor resectionTumor responseDisease progressionSodium MR imagingTumor marginsMR imagingTherapyGlioblastomaTreatment volumeCancer cellsSodium concentration
2012
Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy. Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCranial IrradiationDose Fractionation, RadiationFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsLymphatic MetastasisMaleMeningeal CarcinomatosisMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateConceptsNon-small cell lung cancerWhole brain radiotherapyCell lung cancerLeptomeningeal metastasesTyrosine kinase inhibitorsLandmark analysisIT chemotherapyBrain radiotherapyIntrathecal therapyMedian survivalLung cancerEGFR mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian age 59 yearsReceptor tyrosine kinase inhibitorsMedian overall survivalAge 59 yearsOptimal therapeutic approachSurvival of patientsDevastating complicationOverall survivalLeptomeningeal carcinomatosisRetrospective reviewRetrospective study